Adare Expands European Packaging and Warehousing Capabilities
The CDMO has completed the expansion of its Pessano facility in Milan, Italy, adding increased packaging and warehousing capacity that has already been authorized by the AIFA and is producing validation and commercial batches.
Global technology-driven CDMO that is focused on oral dosage forms, Adare Pharma Solutions, has increased its European packaging and warehousing capacity through the expansion of its Pessano facility in Milan, Italy. The new dedicated packaging and warehouse expansion has already been completed, has been authorized by the Italian medicines agency, AIFA, and is producing validation and commercial batches.
The new packaging hall is 2,800 square meters in size and houses a Marchesini Integra 220S MA260 blister line, featuring integrated Robocombi ‘pick and place’ and SeaVision serialization capabilities. Designed for high-efficiency packaging of tablets and capsules into a variety of formats, such as Aclar, Triplex, PVC, PVDC, and Alu-Alu blisters, the packaging hall offers an annual capacity of more than 50 million blisters.
Additionally, the company has increased its warehouse capacity, which is now large enough for over 900 pallets. Furthermore, the facility has the infrastructure in place to support up to four future packaging lines and dedicated areas for manual packaging, quality control, in-process testing, and serialized materials storage.
“The investment in our Milan facility reflects our ongoing commitment to expanding capacity and capabilities for our customers in Europe,” said Tom Sellig, CEO of Adare Pharma Solutions, in a company press release (1). “With high-speed blistering, modern serialization systems, and a team of experienced packaging experts, our Pessano site is fully equipped to bring customers’ products to market quickly and efficiently.”
With an overall footprint of 20,400 square meters, the Pessano facility also offers R&D services for formulation and process development, and seamless integrated transition to manufacturing. The site offers both clinical and commercial scale production of a wide range of solid dosage forms and can also offer controlled substance and organic solvent capabilities.
Adare’s European capabilities complement its U.S. packaging infrastructure, which includes bottling, blistering, stick pack, and carton packaging services that are supported by integrated serialization and aggregation systems.
In May 2024, Adare announced plans to expand its high potency handling capabilities across both the U.S. and Europe (2). The plans included the addition of a second high potency suite at the Orthodox Street facility in Philadelphia, Pa.; an upgrade to several R&D-to-clinical stage production suites to provide high potency handling in Vandalia facility in Ohio, Ill.; and high potency upgrades to the analytical and formulation laboratories at the Pessano facility (2).
“We have seen demand for high potency handling and packaging continue to increase, with around half of solid dose drugs in development being highly potent,” commented Sellig in a press release about the plans (2). “This proactive investment across our global network of sites will ensure we continue to provide customers with the oral dose capabilities and capacity they will need both now and in the future.”
References
Adare Pharma Solutions. Adare Pharma Solutions Completes Packaging & Warehousing Expansion in Europe. Press Release, Oct. 21, 2025.
Adare Pharma Solutions. Adare Expands Global High Potency Handling & Packaging Capabilities. Press Release, May 1, 2024.